文献速递免疫规划传染病防控与疫情报告

≥12岁人群接种二价COVID-19 mRNA疫苗加强剂后的安全性监测——美国,2022年8月31日至10月23日

Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Persons Aged ≥12 Years - United States, August 31-October 23, 2022.
PubMed 文献 · MMWR Morb Mortal Wkly Rep · 2022-11-04

美国CDC通过v-safe和VAERS监测2022年8月31日至10月23日≥12岁人群接种二价COVID-19 mRNA加强剂后的安全性。v-safe登记者的局部和全身反应常见,但报告就医者不足1%;VAERS收到5542份不良事件报告,95.5%为非严重事件,4.5%为严重事件。

要点

  • v-safe登记者在接种后一周内局部反应报告率60.8%,全身反应报告率54.8%。
  • v-safe登记者中报告接受医疗照护者不足1%。
  • VAERS报告95.5%为非严重事件,4.5%为严重事件。

核心结论

  • 二价加强剂接种后报告的不良事件与单价剂量接种后报告的不良事件一致,医疗服务提供者和患者可对此感到放心。
  • 接种COVID-19疫苗后的健康影响比COVID-19疾病相关的健康影响更不频繁且更不严重。

研究设计与样本

  • CDC审查2022年8月31日至10月23日期间接种二价辉瑞-BioNTech和Moderna加强剂后向v-safe和VAERS报告的不良事件与健康影响。
  • v-safe是CDC建立的基于智能手机的自愿性美国安全性监测系统,VAERS是CDC和FDA管理的美国被动疫苗安全性监测系统。

主要发现

  • 211959名≥12岁v-safe登记者报告接种二价加强剂,接种后一周内局部反应报告率60.8%,全身反应报告率54.8%。
  • v-safe登记者中报告接受医疗照护者不足1%。
  • VAERS收到5542份≥12岁者接种二价加强剂后的不良事件报告,其中95.5%为非严重事件,4.5%为严重事件。

关键数值与推荐

  • 2022年8月31日,FDA授权BNT162b2(辉瑞-BioNTech)和mRNA-1273(Moderna)二价COVID-19疫苗,包含编码原始株和B.1.1.529(Omicron)变异株BA.4和BA.5(BA.4/BA.5)刺突蛋白的mRNA。
  • 二价mRNA疫苗被授权作为单剂加强剂量,在完成基础免疫系列或单价加强剂接种后≥2个月使用;辉瑞-BioNTech二价加强剂被授权用于≥12岁者,Moderna被授权用于≥18岁成人。
  • 2022年9月1日,免疫实践咨询委员会(ACIP)推荐所有≥12岁者接种年龄适宜的二价mRNA加强剂量。

临床怎么用

  • 医疗服务提供者和患者可对二价加强剂接种后报告的不良事件感到放心,其与单价剂量接种后报告的不良事件一致。
  • 接种COVID-19疫苗后的健康影响比COVID-19疾病相关的健康影响更不频繁且更不严重。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

On August 31, 2022, the Food and Drug Administration (FDA) authorized bivalent formulations of BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) COVID-19 vaccines; these vaccines include mRNA encoding the spike protein from the original (ancestral) strain of SARS-CoV-2 (the virus that causes COVID-19) and from the B.1.1.529 (Omicron) variants BA.4 and BA.5 (BA.4/BA.5). These bivalent mRNA vaccines were authorized for use as a single booster dose ≥2 months after completion of primary series or monovalent booster vaccination; Pfizer-BioNTech bivalent booster was authorized for persons aged ≥12 years and Moderna for adults aged ≥18 years.*,† On September 1, 2022, the Advisory Committee on Immunization Practices (ACIP) recommended that all persons aged ≥12 years receive an age-appropriate bivalent mRNA booster dose.§ To characterize the safety of bivalent mRNA booster doses, CDC reviewed adverse events and health impacts reported after receipt of bivalent Pfizer-BioNTech and Moderna booster doses during August 31-October 23, 2022, to v-safe,¶ a voluntary smartphone-based U.S. safety surveillance system established by CDC to monitor adverse events after COVID-19 vaccination, and the Vaccine Adverse Event Reporting System (VAERS),** a U.S. passive vaccine safety surveillance system managed by CDC and FDA (1). During August 31-October 23, 2022, approximately 14.4 million persons aged ≥12 years received a bivalent Pfizer-BioNTech booster dose, and 8.2 million adults aged ≥18 years received a bivalent Moderna booster dose.†† Among the 211,959 registrants aged ≥12 years who reported receiving a bivalent booster dose to v-safe, injection site and systemic reactions were frequently reported in the week after vaccination (60.8% and 54.8%, respectively); fewer than 1% of v-safe registrants reported receiving medical care. VAERS received 5,542 reports of adverse events after bivalent booster vaccination among persons aged ≥12 years; 95.5% of reports were nonserious and 4.5% were serious events. Health care providers and patients can be reassured that adverse events reported after a bivalent booster dose are consistent with those reported after monovalent doses. Health impacts after COVID-19 vaccination are less frequent and less severe than those associated with COVID-19 illness (2).

来源:MMWR Morb Mortal Wkly Rep,查看原文。版权归原作者所有。

引用

  1. Hause AM, Marquez P, Zhang B, et al. Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Persons Aged ≥12 Years - United States, August 31-October 23, 2022. MMWR Morb Mortal Wkly Rep. 2022. PMID: 36327162. doi:10.15585/mmwr.mm7144a3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。